Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2005

01-05-2005 | Brief communication

A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes

Authors: Antonino Musolino, Nadia Naldi, Maria Michiara, Maria A. Bella, Paola Zanelli, Beatrice Bortesi, Marzia Capelletti, Mario Savi, Tauro M. Neri, Andrea Ardizzoni

Published in: Breast Cancer Research and Treatment | Issue 2/2005

Login to get access
Metadata
Title
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes
Authors
Antonino Musolino
Nadia Naldi
Maria Michiara
Maria A. Bella
Paola Zanelli
Beatrice Bortesi
Marzia Capelletti
Mario Savi
Tauro M. Neri
Andrea Ardizzoni
Publication date
01-05-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-7704-4

Other articles of this Issue 2/2005

Breast Cancer Research and Treatment 2/2005 Go to the issue

Report

Immune dysfunction and micrometastases in women with breast cancer

Report

Economic outcomes of breast cancer survivorship: CALGB study 79804

Report

Estimating the number of rate limiting genomic changes for human breast cancer

Report

Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668

Report

Frequent down-regulation of HIVEP2 in human breast cancer

Report

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits